Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

The ATTR-CM market is currently dominated by Pfizer’s Vyndaqel/Vyndamax (tafamidis) and BridgeBio’s recently approved Attruby (acoramidis). Unlike these medications, which are TTR stabilisers ...

Amvuttra now enters a potentially lucrative field largely dominated by Pfizer, whose Vyndaqel (tafamidis) family of transthyretin (TTR) stabilizer drugs won their initial ATTR-CM nods from the FDA ...

Amvuttra (vutrisiran) has become the first RNA interference therapy to be approved for ATTR-CM, and the second challenger to Pfizer's Vyndaqel/Vyndamax (tafamidis) – which became the first drug ...

Alnylam Pharmaceutical’s has secured US Food and Drug Administration (FDA) approval for Amvuttra (vutrisiran), expanding its use to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.

The FDA has approved Alynylam’s RNAi therapy Amvuttra for treating transthyretin amyloid cardiomyopathy (ATTR-CM), positioning it to compete with Pfizer’s Vyndamax and BridgeBio’s Attruby.

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

The ATTR-CM market has grown more competitive following Food and Drug Administration approval of BridgeBio's Attruby in November 2024. There is also competition from Pfizer's Vyndaqel and Vyndamax ...

setting it up to compete with therapies from BridgeBio and Pfizer. Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...